Abstract：
BACKGROUND: Piracetam, a widely recognized nootropic drug, is hypothesized to enhance memory function through its influence on synaptic plasticity and neurotransmitter levels. However, despite its popularity, there remains a lack of conclusive evidence regarding its impact on memory. Therefore, the present study aims to explore the effects of piracetam on memory in individuals with impaired cognitive function, comparing it to a placebo control group.
OBJECTIVE: This study will evaluate how piracetam affects memory function, compared to placebo in adults with impairment in this area.
METHODS: We carried out bibliographical research and meta-analysis of scientific clinical trials comparing memory function in people taking piracetam with those in the placebo group. The PubMed, Dimensions, Embase, and Cochrane Library databases were used. Statistical analysis was performed in R Studio version 4.3.1.
RESULTS: In our analysis, 199 articles were identified, of which we included eighteen studies, comprising a total of 886 patients, of which Piracetam was the treatment option in 442 (49.88 %) patients. Memory enhancement (SMD 0.75; 95 % CI [-0.19; 1.69]; p=0.12; I²=96 %) had no clinical difference between the intervention and the control group.
CONCLUSIONS: Upon the conclusion of this study, it is apparent that we cannot definitively ascertain the impact of piracetam on memory function. Further research is warranted to provide a clearer understanding of the cognitive effects of piracetam in individuals with memory impairment. This investigation serves as a significant contribution to the ongoing quest to elucidate the potential benefits of piracetam in the field of cognitive neuroscience.
OBJECTIVE: This study will evaluate how piracetam affects memory function, compared to placebo in adults with impairment in this area.
METHODS: We carried out bibliographical research and meta-analysis of scientific clinical trials comparing memory function in people taking piracetam with those in the placebo group. The PubMed, Dimensions, Embase, and Cochrane Library databases were used. Statistical analysis was performed in R Studio version 4.3.1.
RESULTS: In our analysis, 199 articles were identified, of which we included eighteen studies, comprising a total of 886 patients, of which Piracetam was the treatment option in 442 (49.88 %) patients. Memory enhancement (SMD 0.75; 95 % CI [-0.19; 1.69]; p=0.12; I²=96 %) had no clinical difference between the intervention and the control group.
CONCLUSIONS: Upon the conclusion of this study, it is apparent that we cannot definitively ascertain the impact of piracetam on memory function. Further research is warranted to provide a clearer understanding of the cognitive effects of piracetam in individuals with memory impairment. This investigation serves as a significant contribution to the ongoing quest to elucidate the potential benefits of piracetam in the field of cognitive neuroscience.
摘要：
背景：吡拉西坦，一种广受认可的促智药，假设通过其对突触可塑性和神经递质水平的影响来增强记忆功能。然而,尽管它很受欢迎，关于它对记忆的影响，仍然缺乏确凿的证据。因此,本研究旨在探讨吡拉西坦对认知功能受损个体记忆的影响,将其与安慰剂对照组进行比较。
目的：本研究将评估吡拉西坦如何影响记忆功能，与安慰剂相比，在这一领域有损害的成年人。
方法：我们对服用吡拉西坦患者与安慰剂组患者的记忆功能进行了文献研究和荟萃分析。PubMed,尺寸,Embase,使用Cochrane图书馆数据库。在RStudio4.3.1版中进行统计分析。
结果：在我们的分析中，确认了199篇文章，其中我们包括18项研究，共有886名患者，其中吡拉西坦是442例（49.88%）患者的治疗选择。记忆增强（SMD0.75;95％CI[-0.19;1.69];p=0.12;I²=96％）在干预组和对照组之间没有临床差异。
结论：本研究结束后，很明显，我们无法确定吡拉西坦对记忆功能的影响。有必要进行进一步的研究，以更清楚地了解吡拉西坦对记忆障碍患者的认知作用。这项研究为阐明吡拉西坦在认知神经科学领域的潜在益处的持续追求做出了重大贡献。
目的：本研究将评估吡拉西坦如何影响记忆功能，与安慰剂相比，在这一领域有损害的成年人。
方法：我们对服用吡拉西坦患者与安慰剂组患者的记忆功能进行了文献研究和荟萃分析。PubMed,尺寸,Embase,使用Cochrane图书馆数据库。在RStudio4.3.1版中进行统计分析。
结果：在我们的分析中，确认了199篇文章，其中我们包括18项研究，共有886名患者，其中吡拉西坦是442例（49.88%）患者的治疗选择。记忆增强（SMD0.75;95％CI[-0.19;1.69];p=0.12;I²=96％）在干预组和对照组之间没有临床差异。
结论：本研究结束后，很明显，我们无法确定吡拉西坦对记忆功能的影响。有必要进行进一步的研究，以更清楚地了解吡拉西坦对记忆障碍患者的认知作用。这项研究为阐明吡拉西坦在认知神经科学领域的潜在益处的持续追求做出了重大贡献。
